Limit the spread. Improve the outcome.

Every time a microorganism becomes resistant to an antibiotic, we lose another vital weapon in the war against infection. Newly resistant microorganisms are emerging—and spreading globally—every day. The result: antimicrobial resistance (AMR). In the very near future, we may be left without any drugs at all to fight serious, resistant infections.1

AMR leads to longer hospital stays, increased mortality, and higher medical costs

2.5 Million
The annual extra hospital days in the European Union (EU)4

€1.5 Million
Extra healthcare costs and productivity losses in the EU per year due to AMR4,5

The annual number of deaths in the EU that are caused by AMR4,5

Better Antibiotic Stewardship with GeneXpert®

When today’s healthcare providers are able to quickly identify whether an infection is present and if it is drug-resistant, we will finally be able to move beyond trial and error. On-demand molecular diagnostics have the potential to help you identify resistance in minutes, rather than days. Cepheid’s GeneXpert® System helps those on the frontlines of resistance prevent the inappropriate use of antimicrobials and preserve our antibiotic weapons―now and in the future. Click here to download our antimicrobial stewardship brochure.

New EU One Health Action Plan Against Antimicrobial Resistance

The European Commission (EC) adopted a new One Health action plan against antimicrobial resistance (AMR) in June 2017. There are three key objectives to the plan:

  1. Make the EU a best practice region through better evidence, coordination, and surveillance
  2. Boost research, development and innovation in order to control the spread of AMR
  3. Shape the global agenda on AMR and the related risks

The EC recognizes that diagnostics are crucial for differentiating between bacterial and viral infections and identifying AMR, so that the most appropriate treatment can be given in a timely manner. Thus, the EC has stated that they will:

  • Support research into the development of new diagnostics tools in particular on-site tests in human and animals to guide practitioners regarding the use of antimicrobials
  • Support the use of IT solutions in developing tools for diagnosing human and animal infections
  • Encourage the uptake of diagnostics in medical and veterinary practice, e.g. through innovation procurement.

The full report can be viewed here.

Related White Papers & Webinars

Related Product Links

Xpert® Carba-R

Xpert® Carba-R

Xpert® Carba-R is a qualitative, on-demand real-time PCR test for the detection and differentiation of KPC, NDM, VIM, OXA-48 and IMP in 48-minutes
Xpert® MRSA/SA Blood Culture

Xpert® MRSA/SA Blood Culture

Accurate detection of MRSA and SA in positive blood culture specimens in about an hour
Xpert® C. difficile BT

Xpert® C. difficile BT

Detection of Clostridium difficile in Around 45 Minutes
Xpert® MTB/RIF Ultra

Xpert® MTB/RIF Ultra

Enhanced performance in detecting drug-sensitive and -resistant Tuberculosis cases in less than 80 minutes

1. World Health Organization. “Antimicrobial resistance: global report on surveillance.” June, 2014.

3. CDC. Antibiotic resistance threats in the United States, 2013. Accessed 12 July 2018.

4. ECDC.  Clostridium difficile infection. Accessed Nov 25 2014. 

5. Gerding DN, et al. Measures to Control and Prevent Clostridium difficile Infection. Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S43-9.

Reference: European Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). June 29, 2017.